Insulin like growth factor-1 receptor: An anticancer target waiting for hit

International Journal of Cancer Research

Volumn 3, Issue 1, 2007, Pages 54-73

  Saxena, Vipin ^a   Hari Narayana Moorthy, N S ^a  

^a UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Antisense; Cancer; IGF IR inhibitors; Insulin; Insulin like growth factors

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CA 074; COMPLEMENTARY RNA; DACTINOMYCIN; EM 164; HYBRID PROTEIN; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR; INTERLEUKIN 8; MONOCLONAL ANTIBODY; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; NVP AEW 541; PODOPHYLLOTOXIN DERIVATIVE; PROTEIN C JUN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SMALL INTERFERING RNA; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C DERIVATIVE; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER RISK; CARCINOGENESIS; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; DRUG DESIGN; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC CONSERVATION; HUMAN; LIGAND BINDING; MELANOMA; MUTATIONAL ANALYSIS; NEPHROBLASTOMA; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RADIOSENSITIVITY; RHABDOMYOSARCOMA; RISK ASSESSMENT; RISK FACTOR; SARCOMA; SIGNAL TRANSDUCTION;

EID: 34249326198     PISSN: 18119727     EISSN: 18119735     Source Type: Journal    
DOI: 10.3923/ijcr.2007.54.73     Document Type: Article

References (131)

1. Adams, T.E., V.C. Epa, T.P. Garrett and C.W. Ward, 2000. Structure and function of the type-1 insulin-like growth factor receptor. Cell Mol. Life Sci., 57: 1052-1093.
2. Agrus-collins, T., L.L. Adams-Camppbell, K.S. Kim and K.J. Cullen, 2000. Insulin-like growth factor-I and breast cancer risk in postmenopausal African-American women. Cancer Detect. Prev., 24: 199-206.
3. Almeida, A., M. Muleris, B. Dutrillaux and B. Malfoy, 2001. The insulin-like growth factor-I, IGF-binding protein-1,2,3 and lung cancer risk in women. Int. J. Cancer, 92: 888-892.
4. Andre, F., J. Rigot, J. Thimonier, C. Montixi, F. Parat and G. Pommier et al., 1999. Integrins. and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int. J. Cancer, 83: 497-405.
5. Andrews, D.W., M. Resnicoff, A.E. Flanders, L. Kenyon, M. Curtis and G. Merli et al., 2001. Results of a pilot study involving the use of an antisense oligodeoxynucleotides directed against the insulin-like growth factor type-I receptor in malignant astrocytomas. J. Clin, Oncol., 19: 2189-2200.
6. Artega, C.L., L.J. Kitten, E.B. Coronado, S. Jacobs, F.C. Kull Jr. and D.C. Allred et al., 1989. Blockade of the type-I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J. Clin. Invest., 84: 1418-1423.
7. Artega, C.L., 1992. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res. Treat., 22: 101-116.
8. Baffa, R., K. Reiss, E.A. El-Gabry, J. Sedor, M.L. Moy and D. Shupp-Byme et al., 2000, Low serum insulin-like growth factor-I (IGF-I): A significant association with prostate cancer. Tech. Urol., 6: 236-239.
9. Bartucci, M., C. Morelli, L. Mauro, S. Ando and E. Surmacz, 2001. Differential insulin-like growth factor-I receptor signaling and function in Estrogen Receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res., 61: 6747-6754.
10. Baxter, R.C., 2000. Insulin like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am. J. Physiol. Endocrinol. Metab., 278: E967-E76.
11. Blum, G., A. Gazit and A. Levitzki, 2000. Substrate competitive inhibitor of IGF-1 receptor kinase. Biochemistry, 39: 15795-15812.
12. Bohula, E.A., M.P. Playford and V. Macaulay, 2003. Targeting the type I insulin-like growth factor receptor as anticancer treatment. Anticancer Drugs, 14: 669-682.
13. Brazil, D.P., J. Park and B.A. Hemmings, 2002. PKB binding proteins: Getting in on the Akt. Cell, 111: 293-303.
14. Brodt, P., A. Samani and R. Navab, 2000. Inhibition of the type-I insulin-like growth factor receptor expression and signaling: Novel strategies for antimetabolic therapy. Biochem. Pharmacol., 60: 1101-1107.
15. Chakravarti, A., J.S. Loeffler and N.J. Dyson, 2002. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res., 62: 200-207.
16. Cheshire, J. L. and A. S. Baldwin Jr., 1997. Synergistic activation of NF-kappa B by tumor necrosis factor alpha and gamma interferon via enhanced Iκ Bα degradation and de novo Iκ, Bβ degradation. Mol. Cell Biol., 17: 6746-6754.
17. Chott, A., Z. Sun, D. Morganstern, J. Pan, T. Li and M. Susani et al., 1999. Tyrosine kinases expressed in vivo [by human prostate cancer bone marrow metastases and loss of type 1 insulin like growth factor receptor. Am. J. Pathol., 155: 1271-1279.
18. Clarke, R.B., A. Howell and E. Anderson, 1997. Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br. J. Cancer, 75: 251-257.
19. Clemmons, D.C., 2001. Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr. Rev., 22: 800-817.
20. Cohen, P., D.M. Peel and R.G. Rosenfeld, 1994a. The IGF axis in the prostate. Horm. Metab. Res., 26: 81-84.
21. Cohen P., D.M. Peehl, B. Baker, F. Liu, R.L. Hintz and R.G. Rosenfeld, 1994b. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab., 79: 1410-1415.
22. Cohen, P., D.M. Peehl, H.C. Graves and R.G. Rosenfeld, 1994c. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J. Endocrinol., 142: 407-415.
23. Cohen, P., 1998. Scrum insulin-like growth factor-1 levels and prostate cancer risk-interpreting the evidence. J. Natl. Cancer Inst., 90: 769-783.
24. Coppola, D., B. Saunders, L. Fu, W. Mao and S.V. Nicosia, 1999. The insulin-like growth factor-1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down regulates their Fas-receptor expression. Cancer Res., 59: 3264-3270.
25. Cutting, C.W., C. Hunt, J.A. Nisbet, J.M. Bland, A.G. Dalgleish and R.S. Kirby, 1999. Serum insulin-like growth factor-I is not a useful marker of prostate cancer. BJU Int., 83: 996-999.
26. Dalle, S., W. Ricketts, T. Imamura, P. Vollenweider and J.M. Olefsky, 2001. Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J. Biol. Chem., 276: 15688-15695.
27. D'Ambrosio, C., A. Ferber, M. Resnicoff and R. Baserga, 1996. A soluble insulin like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibit tumorigenesis, Cancer Res., 56: 4013-4020.
28. Damon, S.E., S.R. Plymate, J.M. Carroll, C.C. Springer, C. Dechsukhum and J.L. Ware et al., 2001. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology, 142: 21-27.
29. Daughaday, W.H. and P. Rotwein, 1989. Insulin like growth factor I and II: peptide, messenger ribonuleic acid and gene structure, serum and tissue concentrations. Endocr. Rev., 10: 68-91.
30. De Leon, D.D., D.M. Wilson, M. Powers and R.G. Rosenfeld, 1992. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. Growth Factors, 6: 327-336.
31. De Meyts, P and J. Whittaker, 2002. Structural biology of insulin and IGF-I receptors: Implication of drug design. Natl. Rev. Drug Discov., 1: 769-783.
32. De Pinho, R.A., 2000. The age of Cancer. Nature, 408: 248-254.
33. Djavan, B., B. Bursa, C. Seitz, G. Soeregi M. Remzi, A. Basharkhas and Wolfram et al., 1999. Insulin-like growth factor-1 (IGF-1), IGF-1 density and IGF-1/PSA ratio for prostate cancer detection. Urology, 54: 603-606
34. Doerr, M. and J. Jones, 1996. The role of integrins and extracellular matrix protein in the insulin-like growth factor-1 stimulated chemotaxis of human breast cancer cells. J. Biol. Chem., 271: 2443-2447.
35. Dreves, J., M. Medinger, C. Schmidt-Gersbach, R. Weber and C. Unger, 2003. Receptor tyrosine kinases: The main target for new anticancer therapy. Curr. Drug Targets, 4: 1134-1121.
36. Dunn, S.E., M. Ehrlich, N.J. Sharp, K. Reiss, G. Solomon and R. Hawkins et al., 1998. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion and metastasis of breast cancer. Cancer Res., 58: 3353-3361.
37. Dupont, J., M. Karas and D. LeRoith, 2000. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J. Biol. Chem., 275: 35893-35901.
38. Elbashir, S.M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber and T. Tuschl, 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411: 494-498.
39. Erin, K.M., L.M. Jennifer, E.D. Nancy, M.G. Lisa, M.C. Katherine, M.Z. Xiao, A.B. Walter, C. Thomas and S. Rajeeva, 2003. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res., 63: 5073-5083.
40. Faveylyukis, S., J.H. Till, S.R. Hubbard and W.T. Miller, 2001. Structure and autoregulation of the insulin-like growth factor-I receptor kinase. Natl. Struct. Biol., 8: 1058-1069.
41. Finne, P., A. Auvinen, H. Koistinen, W.M. Zhang, L. Maattannen and S. Ranniko et al., 2000. Insulin-like growth factor-I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J. Clin. Endocrinol. Metab., 85: 2744-2747.
42. Frasca, F., G. Pandini, P. Scalia, L. Sciacca, R. Mineo and A. Costantino et al., 1999. Insulin receptor isoforms. A: A newly recognized high affinity insulin like growth factor II receptor in fetal and cancer cells. Mol. Cell. Biol., 19: 3278-3288.
43. Garcia-Echeverria, C., J. Brueggen and H.G. Caparo et al., 2003. Characterization of potent and selective kinase inhibitors of IGF-IR. Proc. Am. Assoc. Cancer Res., 44: 1008-1015.
44. Garrouste, F., M. Remacle-Bonnet C. Fauriat, J. Marvaldi, J. Luis and G. Pommier, 2002. Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cell- evidence for a NF-kappa B-dependent survival mechanism. Cell Death Differ., 9: 768-779.
45. Gilmore, A.P., A.J. Valentijn, P. Wang, A.M. Ranger, N. Bundred and M.J. O'Hare et al., 2002. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor. J. Biol. Chem., 277: 27643-27650.
46. Girnita, L., A. Girnita, B. Brodin, Y. Xie, G. Nilsson and J. Landeberg et al., 2000. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res., 60: 5278-5283.
47. Guvakova, M. and E. Surmacz, 1999. The activated insulin-like growth factor-I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas and Paxillin. Exp. Cell Res., 251: 244-255.
48. Hailey, J., E. Maxwell, K. Koukouras, W.R. Bishop, J.A. Pachter and Y. Wang, 2002. Neutralizing anti-insiulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol. Cancer Ther., 1: 1349-1353.
49. Hankinson, S.E., W.C. Willett, G.A. Colditz, D.J. Hunter, D.S. Michaud and B. Derro et al. Circulating concentration of insulin-like growth factor-I and risk of breast cancer. Lancet, 351: 1393-1396.
50. Happerfield, L.C., D.W. Miles, D.M. Barnes, L.L. Thomsen, P. Smith and A. Hanby, 1999. The localization of the insulin-like growth factor receptor I (IGFR-I) in benign and malignant breast tissue. J. Pathol., 155: 1271-1279.
51. Harman, S.M., E.J. Metter, MR. Blackman, P.K. Landis and H.B. Carter, 2000. Serum levels of insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and prostate-specific antigen as predictors of clinical prostate cancer. J. Clin. Endocrinol. Metab., 85: 4258-4265.
52. Hellawell, G.O., G.D. Turner, DR. Davies, R. Poulsom, S.F. Brewster and V.M. Macaulay, 2002. Expression of the type I insulin-like growth factor receptor is upregulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res., 62: 2942-2950.
53. Herbert, Y. and R. Thomas, 2000. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst., 92: 1472-1489.
54. Hill, M.M. and B.A. Hemmings, 2002. Inhibition of protein kinase B/Akt implicatim for cancer therapy. Pharmacol. Ther., 93: 243-251.
55. Hongo, A., C. D'Ambrosio, M. Miura, A. Morrione and R. Baserga, 1996. Mutational analysis of the mitogenic and receptor transforming activities of the insulin-like growth factor-I. Oncogene, 12: 1231-1238.
56. Huynf H., R.M. Seyam and G.B. Brock, 1998. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor-I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein-3. Cancer Res., 58: 215-218.
57. Jacobs, S., S. Cook, M.E. Svoboda and J.J. Van Wyk, 1986. Interaction of the monoclonal antbodies alpha IR-1 and alpha-IR-3 with insulin and somatomedin-C receptor. Endocrinology, 118: 223-226.
58. Jernstrom, H. and E. Barrett-Connor, 1999. Obesity, weight change, fasting insulin, pro-insulin, C-peptide and insulin-like growth factor levels in women with and without breast cancer. The Rancho Bernardo Study. J. Women Health Gend. Based Med., 8: 1265-1272.
59. Kalebic, T., M. Tsokos and L.J. Helman, 1994. In vivo treatment with antibody against lGF-I receptor suppresses growth of human rhabdomyosarcoma and down regulates p34cdc2. Cancer Res., 54: 5531-5534.
60. Kaleko, M., W.J. Rutter and A.D. Miller, 1990. Overexpression of the human insulin like growth factor-I receptor promotes ligand dependent neoplastic transformation. Mol. Cell Biol., 10: 464-473.
61. Katia, S., C.M. Maria, N. Giordano, L. Pier-Luigi, L. Stella, B. Stefania, C. Stefania, P. Stefania, Z. Diana, S. Massimo, G.E. Carlos, H. Francesco and P. Piero, 2005. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res., 65: 3868-3876.
62. Kato, H., T.N. Faria, B. Stannard, C.T. Roberts Jr. and D. LeRoith 1993. Essential role of tyrosine residues 1131,1135 and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. J. Biol. Chem., 268: 2655-2661.
63. Khandwala, H.M., I.E. McCutcheon, A. Flyvbjerg and K.E. Friend, 2000 The effect of insulin like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev., 21: 215-244.
64. LeRoith, D., H. Werner, D. Beitner-Johnson and C.T. Roberts Jr, 1995. Molecular and cellular aspect of the insulin like growth factor I receptor. Endocr. Rev., 16: 143-63.
65. Li, S.L., J. Kato, I.B. Paz, J. Kasuya and Y. Fujita-Yamaguchi, 1993. Two new monoclonal antibodies against the alpha subunit of die human insulin-like growth factor-I receptor. Biochem. Biophys. Res. Commun., 196:92-98.
66. Li, S.L., S.J. Liang, N. Guo, A.M. Wu and Y. Fujita-Yamaguchi, 2000. Single-chain antibodies against human insulin-like growth factor-I receptor. Cancer Immunol. Immunother., 49, 243-252.
67. Long, L., R. Navab and P. Brodt, 1998. Regulation of the Mr 72,000 type IV collagenase by the type-I insulin-like growth factor receptors. Cancer Res., 58: 3243-3247.
68. Ludwig, D.L., D. Burtrum and D. Lu, et al., 2003. A fully human monoclonal antibody to the human IGF-I receptor that blocks ligand-dependent signaling and inhibit growth of multiple human tumors in nude mice. Proc. Am. Assoc. Cancer Res., 44: 761-768.
69. Lukanova, A., P. Toniolo, A. Akhmed khan, C. Biessy, N.J. Haley and R.E. Shore et al., 2001. A prospective study of insulin-like growth factor-I, IGF-binding proteins-1,-2,-3 and lung cancer risk in women. Int. J. Cancer, 92: 888-892.
70. Ma, J., M.N. Pollak and E. Giovannucci et al., 1999. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst., 91: 620-625.
71. Macauley, V.M., A.J. Salisbury, E.A. Bohula, M.P. Playford, N.I. Smorodinskyand Y. Shiloh, 2001. Down regulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm Kinase. Oncogene, 20: 4029-4047.
72. Mathieu, M., F, Vignon, F. Capony and H. Rochefort, 1991. Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: A receptor saturation mechanism to increase the secretion of lysosomal. proenzymes. Mol. Endocrinol., 5: 815-822.
73. Mauro, L., D. Sisci, M. Bartucci, M. Salerno, J. Kim and T. Tam et al., 1999. SHC-alpha5 beta 1 integrin interaction regulate breast cancer cell adhesion and motility. Exp. Cell Res., 252: 439-448.
74. Mauro, L., M. Salerno, C. Morelli, T. Boterberg, M.E. Bracke and E. Surmacz, 2003. Role of IGF-I receptor in regulation of cell-cell adhesion: implication in cancer development and progression. J. Cell Physiol., 194: 108-116.
75. Meyer, G.E., E. Shelde, B. Kim and E.L. Feldman, 2001. Insulin like-growth factor I stimulates motility in human neuroblastoma cells. Oncogene, 20: 7542-7550.
76. Mira, E., S. Manes, R.A. Lacalle, G. Marques and A.C. Martinez, 1999. Insulin-like growth factor-I triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology, 140: 1657-1664.
77. Muller, M., M. Dietel, A. Turzynski and K. Wiechen, 1998. Antisense phosphorothioate oligodeoxynucleotides, down regulation of the insulin-like growth factor-I receptor in ovarian cancer cells. Int. J. Cancer, 17, 567-571.
78. Munshi, S., M. Kornienko, D.L. Hall, J.C. Reid, L. Waxman and S.M. Stirdivant et al., 2002. Crystal structure of Apo, unactivated insulin-like growth factor-I receptor kinase: Implication for inhibitor specificity. J. Biol. Chem., 277: 38797-38802.
79. Nakamura, K., A. Hongo, J. Kodama, Y. Miyagi, M. Yoshinouchi and T. Kudo, 2000. Down regulation of the insulin-like growth I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res., 60: 760-765.
80. Neuenschwander, S., C.T. Roberts Jr. and D. LeRoith, 1995. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor-I receptor antisense ribonucleic acid. Endocrinology, 136: 4298-4303.
81. Nicholson, K-M. and N. Anderson, 2002. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal., 14: 381-395.
82. O'Connor, R., C. Fennelly and D. Krause, 2000. Regulation of survival signals from the insulin-like growth factor-I receptor. Biochem. Soc. Trans., 28: 47-51.
83. Palmqvist, R., G. Hallmans, S. Rinaldi, C. Biessy, R. Stenling and E. Ribolo et al., 2002. Plasma insulin-like growth factor 1, insulin-like growth factor binding protem-3 and risk of colorectal cancer: a prospective study in northern Sweden. Gut 50: 642-646.
84. Pandini, G., F. Frasca, R. Mineo, L. Sciacca, R. Vigneri and A. Belfiore, 2002. Insulin/insulin-like growth factor 1 hybrid receptors have different biological characteristics depending on the insulin receptor isoforms involved. J. Biol. Chem., 277: 39684-39695.
85. Pautsch, A., A. Zoephel, H. Ahorn, W. Spevak, R. Hauptnann and H. Nar, 2001. Crystal structure of bisphosphorylated IGF-I receptor kinase: insight into domain movements upon kinase activation. Structure (comb), 9: 955-965.
86. Pavelic, J., L. Pavelic, J. Karadza, S. Krizanac, J. Unesic and S. Spaventi et al., 2002. Insulin-like growth factor family and combined antisense approach in therapy of lung carcinoma. Mol. Med., 9: 955-965.
87. Pennisi, P.A., V. Barr, N.P. Nunez, B. Stannard and D. LeRoith, 2002. Reduced expression of insulin-like growth factor-I receptors in mcf-7 breast cancer cells leads to a more metastatic phenotype. Cancer Res., 62: 6529-6537.
88. Peruzzi, F., M. Prisco, M. Dews, P. Salomoni, E. Grassili, G. Romano, et al., 1999. Multiple signaling pathways of the insulin-like growth factor-I receptor in protection from apoptosis. Mol. Cell Biol., 19: 7203-7215
89. Pietrzkowski, Z., D. Wernicke, P. Porcu, B.A. Jameson and R. Baserga, 1992. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor-I. Cancer Res., 52: 6447-6451.
90. Pietrzkowski, Z., G. Mulholland, L. Gomella, B.A. Jameson, D. Wernicke and R. Baserga, 1993. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor-1. Cancer Res., 53: 1102-1106.
91. Probst-Hensch, N.M., J.M. Yuan, F.Z. Stanczyk, Y.T. Gao, R.K. Ross and M.C. Yu, 2001. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: Association with colorectal cancer in a cohort of Chinese men in Shanghai. Br. J. Cancer, 85: 1695-1699.
92. Reinmuth, N, W. Liu, F. Fan, Y.D. Jung, S.A. Ahmad and O. Stoeltzing et al., 2002. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin. Cancer Res., 8: 3259-3269.
93. Reiss, K., J.Y. Wang, G. Romano, X. Tu, F. Peruzzi and R. Baserga, 2001. Mechanism of regulation of cell adhesion and motility by insulin receptor substrate-I in prostate cancer cell. Oncogene, 20: 490-500.
94. Resnicoff, M., C. Sell, M. Rubin, D. Coppola, D. Ambrose, R. Baserga et al., 1994. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type I insulin-like growth factor receptor. Cancer Res., 54: 4848-4850.
95. Resnicoff, M., D. Abraham, W. Yutanawiboonchi, H.L. Rotman, J. Kajstura and R. Rubin et al., 1995a. The insuhn-like growth factor-I receptor protects tumor cells from apoptosis in vivo. Cancer Res., 55: 2463-2469.
96. Resnicoff, M., J.L. Burgaud, H.L. Rotman, D. Abraham and R. Baserga, 1995b. Correlation between apoptosis, tumorigenesis and levels of insulin-like growth factor I receptors. Cancer Res., 55: 3739-3741.
97. Rininsland, F., T.R. Johnson, C.L. Chernicky, E. Schulze, P. Buifeind and J. Ilan, 1997. Suppression of insulin-like growth factor type-I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc. Natl. Acad. Sci. USA., 94: 5854-5959
98. Romano, G., M. Prisco, T. Zanocco-Marani, F. Peruzzi, B. Valentinis and R. Baserga, 1999. Dissociation between resistance to apoptosis and the transformed phenotype in IGF-I receptor signaling. J. Cell Biochem., 72: 294-310.
99. Rother, K.I. and D. Accili, 2000. Role of insulin receptors and IGF-receptors in growth and development. Pediatr. Nephrol., 14: 558-561.
100. Ruan, W., L. Powell-Braxton, J.J. Kopchick and D.L. Kleinberg, 1999. Evidences that insulin-like growth factor I and growth hormones are required for prostate gland development. Endocrinology, 140: 1984-1989.
101. Sachdev, D., S.L. Li, J.S. Hartell, Y. Fujita-Yamaguchi, J.S. Miller and D. Yee, 2003. A chimeric humanized single chain antibody against type-I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogerfic effect of IGF-I. Cancer Res., 63: 627-635.
102. Satyamoothy, K, G. Li, B. Vaidya, D. Patel and M. Herlyn, 2001. Insulin-like growth factor-I induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res., 61: 7318-7324.
103. Satyamoothy, K., G. Li, B. Vaidya, J. Kalabis and M. Herlyn, 2002. Insulin like growth factor-I-induced migration of melanoma cells is mediated by inerleukin-8 induction. Cell Growth Differ., 13: 87-93.
104. Schnarr, B., K. Strunz, J. Ohsam, A. Benrier, J. Wacker and D. Mayer, 2002. Down regulation of insulin-like growth factor-I receptor and insulin receptor substrate-I expression in advanced human breast cancer. Int. J. Cancer, 89: 506-513.
105. Scotlandi, K., S. Benini, P. Nanni, P.L. Lollini, G. Nicoletti, L. Landiuzzi, et al., 1998. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in mice. Cancer Res., 58: 4127-4131.
106. Scotlandi, K., S. Avnet, S. Benini, M.C. Manara, M. Serra and V. Cerisano et al., 2002a. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemo sensitivity in Ewing's sarcoma cells. Int. J. Cancer, 101: 11-16.
107. Scotlandi, K., S. Benini P. Nanni, P.L. Lollini, G. Nicoletti and L. Landiuzzi et al., 2002b. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemoselectivity in Ewing's sarcoma Cells. Int. J. Cancer, 101: 11-16.
108. Shaw, L.M., 2001. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha 6 beta 4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol. Cell Biol., 21: 5082-5093.
109. Shepherd, P.R., D. Withers and K. Siddle, 1998. Phosphoinositide 3-kinase: The key switch mechanism in insulin signaling. Biochem. J., 333: 471-490.
110. Sperandio, S.I. DeBelle and D.E. Bredesen, 2002. An alternative nonapoptotic form of programmed cell death Proc. Natl. Acad. Sci. USA., 97: 14376-14381.
111. Stattin, P., A. Bylund, S. Rinaldi, C. Biessy, H. Dechaud, U.H. Stenman et al., 2000. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins and prostate cancer risk: A prospective study. J. Natl. Cancer Inst., 92: 1910-1917.
112. Surmacz, E., C. Sell, J. Swantek, H. Kato, C.T. Roberts Jr., D. LeRoith and R. Baserga, 1995. Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth-I receptor. Exp. Cell Res., 218: 370-380.
113. Surmacz, F., 2000. Function of the IGF-I receptor in breast cancer. J. Mammary Gland Biol. Neopl., 5: 95-105.
114. Tanno, S., Y. Mitsuuchi, D.A. Altomare, G.H. Mao and J.R. Testa, 2001. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res., 61: 589-593.
115. Tennant, M.K., J.B. Thrasher, P.A. Twomey, R.H. Drivdahl, R.S. Brinbaum and S.R. Polymate, 1996. Protein and messenger ribonucleic acid (mRNA) for the type I insulin like growth (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab., 81: 3774-3782.
116. Torring, N., L. Vinter-Jensen, S.B. Pedersen, F.B. Sorensen, A. Flyvbjerg and E. Nexo, 1997. Systemic administration of insulin-like growth factor-I (IGF-I) causes growth of the rat prostate. J. Urol., 158: 222-227.
117. Trojan, L.A., P. Kopinski, L.A. Wei Max, A. Glogowska and J. Czarny et al., 2002. IGF-I from diagnostic to triple-helix gene therapy of solid tumors. Acta. Biochem. Pol., 49: 979-990.
118. Turner, B.C., B.G. Haffty, L. Narayanan, J. Yuan, P.A. Havre and A.A. Gumbs et al., 1997. Glazer insulin like growth factor-I receptor overexpression mediates cellular radioresistence and local breast cancer recurrence after lumpectomy and radiation. Cancer Res., 57: 3079-3083.
119. Ullrich, A., A. Gray, A.W. Tam, T. Yang-Fong, M. Tsubokawa and C. Collins, 1986. Insulin-like growth factor I receptor primary structure comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J., 5: 2503-2512.
120. Vadgama, J.V., Y. Wu, G. Datta, H. Khan and R. Chillar, 1999. Plasma insulin-like growth factor-I and serum IGF-binding protein-3 can be associated with the progression of breast cancer and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology, 57: 330-340.
121. Vuori, K. and E. Ruoslahti, 1994. Association of insulin receptor substrate-1 with integrins. Science, 266: 1576-1587.
122. Wen, B., E. Deutsch, E. Marangoni, V. Frascona, L. Maggiorella and B. Abdulkarim et al., 2001. Tryphostin AG1024 modulates radiosensitivity in human breast cancer cells. Br. J. Cancer, 85: 2017-2021.
123. Werner, H., E. Karnieli, F.J. Rauscher and D. LeRoith, 1996. Wild type and mutant p53 differentially regulate transcription of the insulin like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA., 93: 8313-8323.
124. White, M.F., 1994. The IRS-signaling system: a network of docking proteins that mediates insulin action. Mol. Cell Biochem., 182: 3-11.
125. White, M.F., 2002. IRS protein and the common path to diabetes. Am. J. Physiol. Endocrinol. Metab., 283: E413-422.
126. Wolk, A., C.S. Maritzoros, S.O. Andersson R. Bergstrom, L.B. Signorello and P. Lagiou et al., 1998. Insulin-like growth factor I and prostate cancer risk: a population based case control study. J. Natl. Cancer Inst., 90: 911-915.
127. Yu, H., M.R. Spitz, J. Mistry, J. Gu W.K. Hong and X. Wu, 1999. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J. Natl. Cancer Inst., 91: 151-156.
128. Zhang, D. and P. Brodt, 2003. Type-I insulin-like growth factor regulates MTI-MMP synthesis and tumor invasion via PI-3 kiriase Akt signaling. Oncogene, 22: 974-982.
129. Zia, F., S. Jacobs, F. Kull Jr., F. Cuttitta, J.L. Mulshine and T.W. Moody, 1996. Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J. Cell. Biochem. Suppl., 24: 269-275.
130. Zong, C.S., L. Zeng, Y. Jiang, H.B. Sadowski and L.H. Wang, 1998. Stat 3 plays an important role in oncogenic Ras- and insulin-like growth factor I receptor-induced anchorage-independent growth. J. Biol. Chem., 273: 28065-28072.
131. Zong, C.S., J. Chan, D.E. Levy, C. Horvath, H.B. Sadowski and L.H. Wang, 2000. Mechanism of STAT 3 activation by insulin-like growth factor-I receptor. J. Biol. Chem., 275: 15099-15105.